Santhera Pharmaceuticals Appoints New Commercial Head to Drive Growth

Santhera names Marc Clausse as new Chief Commercial Officer to accelerate the worldwide commercialization of its DMD therapy AGAMREE, effective June 2026.

Santhera Pharmaceuticals is positioning itself for its next phase of expansion with a key leadership appointment. The company has named Marc Clausse as its new Chief Commercial Officer, a move designed to accelerate the worldwide commercialization of its flagship therapy, AGAMREE. This strategic hire brings a seasoned industry specialist with deep expertise in rare diseases to helm the company's commercial operations.

Leadership Transition Aligns with Commercial Push

Effective June 1, 2026, Marc Clausse will assume the role, succeeding Geert Jan van Daal, who is retiring after an eleven-year tenure with Santhera. Clausse joins from Mirum Pharmaceuticals, bringing more than 25 years of experience within the life sciences sector. His background is viewed as a critical asset for enhancing international patient access to AGAMREE, a treatment for Duchenne Muscular Dystrophy (DMD).

The timing of this appointment is strategically significant. With the European launch of AGAMREE already underway, the company's focus is now shifting toward scaling its global commercial platform. Clausse will report directly to CEO Dario Eklund and will be responsible for directing the overarching global marketing strategy to maximize the drug's potential.

Market Reaction and Technical Positioning

Investors have responded positively to the news. Santhera's shares closed at €18.36 on Tuesday, reinforcing a strong upward trend for the year. The stock has recorded a substantial gain of approximately 34% since the start of the year, bringing its 52-week high of €18.74—set in mid-February—back into view as a near-term target.

Despite trading close to its yearly peak, technical indicators present a nuanced picture. The Relative Strength Index (RSI) reading of 21.8 suggests the stock is in technically oversold territory. Furthermore, the current share price remains significantly above its 200-day moving average of €13.81, underscoring a sustained positive long-term trend.

The operational execution of Santhera's expanded growth strategy will commence with Clausse's arrival in June 2026. In the coming months, market participants will be closely monitoring whether the new commercial leadership can tangibly accelerate market access in additional regions. Should the current momentum persist, surpassing the existing annual high of €18.74 will be the next pivotal challenge for the share price.